The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED.
Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine, but its short-term effectiveness in the ED context is unknown. Unlike other migraine treatments used in the ED, eptinezumab can rapidly interrupt the migraine process, potentially also preventing migraine from coming back in the short term.
Most patients with a diagnosis of migraine have no access to preventative therapies. This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack. Administering this medication in the ED may stop the attack more effectively compared to current therapies.
This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED. The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED, what other medications they might need alongside eptinezumab, and how they feel overall.

开始日期2024-09-30

申办/合作机构

Healthtech Connex, Inc.

[+3]

NCT06557850 / Recruiting临床1期

Interventional, Open-label, Single-group, Long-term Follow-up Trial of Lu AG22515 in Patients With Moderate-to-severe Thyroid Eye Disease

This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease.
In people with TED, the healthy tissue behind and around the eye becomes inflamed and swollen. One of the key symptoms of TED is proptosis (bulging eyes). The main goal of this trial is to learn whether treatment with Lu AG22515 improves proptosis in participants with moderate-to-severe TED.

开始日期2024-09-19

申办/合作机构

H. Lundbeck A/S

NCT06578585 / Recruiting临床1期

Interventional, Randomized, Double-blind, Placebo-controlled Trial Investigating the Safety and Tolerability of Lu AG09222 When Coadministered With Ubrogepant in Participants With Migraine

The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.

开始日期2024-09-13

申办/合作机构

H. Lundbeck A/S

100 项与 H. Lundbeck A/S 相关的临床结果

登录后查看更多信息

0 项与 H. Lundbeck A/S 相关的专利（医药）

登录后查看更多信息

2,103

项与 H. Lundbeck A/S 相关的文献（医药）

2024-12-31·Journal of medical economics

A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia

Article

作者: Schein, Jeff ; Cloutier, Martin ; Urganus, Annette ; Aggarwal, Jyoti ; Gauthier-Loiselle, Marjolaine ; Chan, Deborah ; Bungay, Rebecca ; Guerin, Annie ; Grossberg, George

AIMS:

To describe and compare clinical characteristics, healthcare costs, and institutionalization/mortality outcomes among patients with and without agitation associated with Alzheimer's dementia (AAD).

METHODS:

Data from the Reliant Medical Group database (01/01/2016-03/31/2020) were used, including claims, electronic medical records, and clinical information/physician notes abstracted from medical charts. Patients aged ≥55 years with Alzheimer's dementia (AD) were observed during a randomly selected 12-month study period after AD diagnosis. Using information recorded in medical charts, patients were classified into cohorts based on experiencing (agitation cohort) and not experiencing (no agitation cohort) agitated behaviours during the study period. Entropy balancing was used to create reweighted cohorts with similar characteristics. Study outcomes (patient demographic and clinical characteristics, treatments received, healthcare costs, institutionalization and death events) were compared between cohorts; agitation characteristics were described for the agitation cohort only.

RESULTS:

Among 711 patients included in the study, 240 were classified in the agitation cohort and 471 in the no agitation cohort. After reweighting, several comorbidities were more frequently observed in the agitation versus no agitation cohort, including infection, depression, and altered mental status. Use of antidepressants, anticonvulsants, antipsychotics, and antianxiety medications was more common in the agitation versus no agitation cohort. Common agitated behaviours included hitting (20.8%), pacing/aimless wandering (17.5%), and cursing/verbal aggression (15.0%). Total all-cause healthcare costs were $4287 per-patient-per-year higher in the agitation cohort versus no agitation cohort (p = 0.04), driven by higher inpatient costs. Death was more common and time to death and institutionalization were shorter in the agitation versus no agitation cohort.

LIMITATIONS:

Results may not be generalizable to the US population with AD.

CONCLUSIONS:

Among patients with AD, agitation was associated with shorter time to death/institutionalization and increased comorbidities, medication use, and healthcare costs, highlighting the additional clinical and economic burden that agitation poses to patients and the healthcare system.

2024-08-01·Biological psychiatry

Polygenic Risk of Mental Disorders and Subject-Specific School Grades

Article

作者: Mortensen, Preben Bo ; Vilhjálmsson, Bjarni Jóhann ; Plana-Ripoll, Oleguer ; Børglum, Anders ; Mors, Ole ; Munk-Olsen, Trine ; Yilmaz, Zeynep ; Holde, Katrine ; Rajagopal, Veera Manikandan ; Agerbo, Esben ; Demontis, Ditte ; Bulik, Cynthia M ; Grove, Jakob ; Albiñana, Clara ; Petersen, Liselotte Vogdrup ; McGrath, John J ; Jefsen, Oskar Hougaard

BACKGROUND:

Education is essential for socioeconomic security and long-term mental health; however, mental disorders are often detrimental to the educational trajectory. Genetic correlations between mental disorders and educational attainment do not always align with corresponding phenotypic associations, implying heterogeneity in the genetic overlap.

METHODS:

We unraveled this heterogeneity by investigating associations between polygenic risk scores for 6 mental disorders and fine-grained school outcomes: school grades in language and mathematics in ninth grade and high school, as well as educational attainment by age 25, using nationwide-representative data from established cohorts (N = 79,489).

RESULTS:

High polygenic liability of attention-deficit/hyperactivity disorder was associated with lower grades in language and mathematics, whereas high polygenic risk of anorexia nervosa or bipolar disorder was associated with higher grades in language and mathematics. Associations between polygenic risk and school grades were mixed for schizophrenia and major depressive disorder and neutral for autism spectrum disorder.

CONCLUSIONS:

Polygenic risk scores for mental disorders are differentially associated with language and mathematics school grades.

2024-03-03·Current medical research and opinion

Patient journey of civilian adults diagnosed with posttraumatic stress disorder—A chart review study

Article

作者: Guérin, Annie ; Urganus, Annette ; Cloutier, Martin ; Gagnon-Sanschagrin, Patrick ; Aggarwal, Jyoti ; Davis, Lori L. ; Maitland, Jessica ; Bellefleur, Remi ; Bedard, Jerome

OBJECTIVE:

To assess the journey of individuals from experiencing a traumatic event through onset of symptoms, diagnosis, and treatment of posttraumatic stress disorder (PTSD).

METHODS:

Patient- and psychiatrist-level data was collected (02/2022-05/2022) from psychiatrists who treated ≥1 civilian adult diagnosed with PTSD. Eligible charts covered civilian adults diagnosed with PTSD (2016-2020), receiving ≥1 PTSD-related treatment (selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], atypical antipsychotics [AAs]), and having ≥1 medical visit in the last 12 months. Collected information included clinical and treatment characteristics surrounding the PTSD diagnosis.

RESULTS:

A total of 273 psychiatrists contributed data on 687 patients with PTSD (average age 36.1; 60.4% female). On average, the traumatic event and symptom onset occurred 8.7 years and 6.5 years prior to PTSD diagnosis, respectively. In the 6 months before diagnosis, 88.9% of patients had received a PTSD-related treatment. At time of diagnosis, 87.8% of patients had intrusion symptoms and 78.9% had alterations in cognition/mood; 41.2% had depressive disorder and 38.7% had anxiety. Diagnosis prompted treatment changes for 79.3% of patients, receiving treatment within 1.9 months on average, often with a first-line SSRI as either monotherapy (52.8%) or combination (24.9%). At the end of the 24-month study period, 34.4% of patients achieved psychiatrist-recorded remission. A total of 23.0% of psychiatrists expressed dissatisfaction with approved PTSD treatments, with 88.3% at least somewhat likely to prescribe AAs despite lack of FDA approval.

CONCLUSION:

PTSD presents heterogeneously, with an extensive journey from trauma to diagnosis with low remission rates and limited treatment options.

353

项与 H. Lundbeck A/S 相关的新闻（医药）

2024-11-04

·生物制药小编

癫痫药物的春天来了？

癫痫治疗领域再次迎来重磅交易。近日，灵北制药宣布以26亿美元的价格，收购Longboard Pharmaceuticals。后者的核心管线是bexicaserin，一款高选择性的5-HT2C超级激动剂，用于治疗难治性癫痫DEE，已完成二期临床并获得突破疗法认证。收购消息传出后，Longboard股价大涨超50%。年初至今，由于公布bexicaserin 1b/2a期研究的积极顶线数据，其股价一路上涨，涨幅超过888%。灵北制药是丹麦精神疾病与神经系统疾病领域先驱，也是为数不多专注于CNS疾病的制药公司之一。大手笔收购Longboard，也意味着其在神经学和罕见疾病这片充满挑战却又极具潜力的领域中，更进一步。尽管失败如影随形，但是，随着越来越多药企尝试征服这一CNS研发高地，或许，正如阿尔兹海默症般，经历数十载漫长黑夜，癫痫药物的开发正在迎来春天。严重未满足的临床需求癫痫是最常见的中枢神经系统疾病（CNS）之一，影响着全球5000多万人。作为一种高致残性的慢性神经系统疾病，癫痫以其发作的不可预测性对患者生活造成极大影响。对于患者来说，治疗首选方案是抗癫痫发作药物（ASMs），这也是最基础、最重要的治疗手段。过去几十年，已有超过20种ASMs问世，从第一代演变至第三代，然而，疗效有限、副作用明显等问题依然影响着癫痫患者的治疗效果，是目前ASMs亟待解决的问题。比如，第一代ASMs包括苯巴比妥、苯妥英钠、卡马西平、丙戊酸、氯硝西泮等。这些药物在早期的癫痫治疗中发挥了重要作用，但其副作用较为明显，如嗜睡、头晕、恶心等，并且药物之间的相互作用较多，需要严格控制剂量和监测不良反应。而第二代ASMs如加巴喷丁、拉莫三嗪、托吡酯、左乙拉西坦、普瑞巴林等。相比第一代药物，副作用有所减少，药物间的相互作用也较少，是目前治疗的主流。但是，在过去的30年中，二代ASMs的广泛使用似乎并未使癫痫药物治疗的整体疗效和耐受性得到提高。近几年上市的三代ASMs，能否打破目前的停滞状态还有待于进一步观察。与之相比，还有一类患者的治疗困境尤为突出。尽管WHO指出70%的癫痫患者通过ASMs治疗可达到消除癫痫发作，但仍有约30%的患者对现有ASMs不敏感，癫痫发作无法得到有效控制，称为难治性癫痫。这类患者由于异质性、耐药性导致可选择的药物十分匮乏。典型如全球神经系统疾病负担的第三大元凶——DEEs。这也是灵北制药此次收购布局的领域。 DEEs是一组罕见的神经系统疾病，通常在婴儿期发作，具有难治性癫痫发作和发育迟缓和/或倒退的特征。同时DEEs涵盖了超过25种不同的综合征，包括Dravet综合征（DS）、Lennox-Gastaut综合征（LGS）、结节性硬化症（TSC）、CDKL5缺乏症（CDD）等，其中仅有4种有获批药物。虽然这些综合征单独被认为是孤儿病，但据估计在美国大约有22万患者受到DEEs综合征的影响。作为一组疾病，其总体发病率达到（0.27～0.54）/1000例新生儿，癫痫发作的影响还伴随到他们的儿童、成年时期，甚至可能导致过早死亡或者避免死亡但留下严重的神经系统残疾。而在治疗方面，大多数DEE患者采用多种药物联合治疗，并随时间更换药物。然而，几乎所有患者都经历了多次癫痫发作和治疗相关的副作用。换句话说，DEEs治疗领域存在严重未满足的临床需求，需要更多更好的治疗选择。潜在破局者bexicaserin 灵北制药此次收购Longboard，看中的就是bexicaserin有成为DEEs领域破局者的潜力。 Bexicaserin是由Longboard研发的新型口服、高选择性、中枢作用的5-HT2C超级激动剂，正在开发用于治疗与DEE相关的癫痫发作，例如Dravet综合征、Lennox-Gastaut综合征、结节性硬化症、CDKL5缺乏症和其他癫痫性疾病。 5-HT是一种重要的脑内神经递质，与神经元的兴奋-抑制平衡密切相关，其受体包含多种亚型。其中5-HT2C受体，是一种G蛋白偶联受体，这也是Longboard一直专注的成药靶点，已被确定为治疗肥胖和其他CNS疾病(如精神分裂症和药物成瘾)的有效药物靶点。但是，由于5-HT2C受体与其他两个5-HT2亚型(5-HT2A和5-HT2B)具有约50%的序列相似性，因此导致大量药物存在脱靶效应，或因选择性差从而与5-HT2A、5-HT2B结合，产生幻觉和心脏瓣膜病等副作用。比如2020年获批用于治疗Dravet综合征的5-HT2激动剂Fintepla，其药物标签上有一个黑框警告，该药物的活性成分与瓣膜性心脏病和肺动脉高压的风险有关。因此，开发高选择性5-HT2C受体激动剂，作为潜在治疗DEEs药物更具前景。临床前试验已经验证了bexicaserin的5-HT2C受体高选择性以及相比内源性5-HT能诱导更强的细胞反应。与Fintepla相比，bexicaserin对5-HT2C受体的选择性增加，从而减少了与5-HT2A和5-HT2B激动剂相关的潜在不良反应的可能性。今年1月，Longboard公布了bexicaserin 1b/2a期研究的积极顶线数据，结果显示：在主要疗效终点方面，在DEE研究人群中，bexicaserin使可数运动性癫痫发作的中位数减少53.3%，远高于安慰剂组的20.8%。另外，Longboard还公布了在DS、LGS和其他DEE亚组中的数据，癫痫发作的中位数降低分别为72.1%、48.1%和61.2%。这一数据，与此前Fintepla治疗DS的三期临床数据不相上下。而在安全性方面，bexicaserin表现似乎更优。此前Fintepla各组患者经历了至少一次严重TEAE，bexicaserin最常见的不良事件则是嗜睡、食欲下降、便秘、腹泻和嗜睡。数据公布后，Longboard的股价一路上涨，截至收购消息公布前，涨幅已经接近600%，而年初至今，其股价涨幅超过888%。 7月，bexicaserin获得FDA突破性疗法认定，用于2岁以上DEEs患者的治疗。9月以来，Longboard正式开启了bexicaserin针对DS的Ⅲ期试验。优秀的临床表现也成功吸引了灵北制药入局，并对其报以厚望，计划在2028年第四季度正式推出，预计bexicaserin全球销售额达到15-20亿美元。灵北制药总裁Charl van Zyl表示，此次收购是“变革型的交易”，将成为灵北神经罕见病的基石，有可能推动未来十年的发展。癫痫药物的春天来了？由于血脑屏障阻碍、致病机制不明、缺乏有效疾病模型等原因，包括癫痫在内的CNS疾病新药研发困难重重。幸运的是，包括Longboard在内的biotech在不断努力，包括灵北制药、艾伯维、武田等大药企的加入，也在不断增强我们对于征服该领域的信心。去年底，艾伯维宣布以87亿美元收购Cerevel，后者管线较多，其中之一包括Darigabat，用于治疗难治性癫痫和恐慌症，已经进入2期临床。整体来看，除了前文提及的bexicaserin、Fintepla，还有一些已上市以及很多处于研究中的新型抗癫痫药物。根据DelveInsight公司提供的数据，目前有超过75家药企在开发癫痫药物，在研药物超过90个。可以说，这些新一代ASMs的研究和开发为癫痫患者提供了更多治疗选择。而去年以来，癫痫领域在基础、临床研究方面取得了诸多进展。比如加拿大药企Xenon，其核心管线XEN1101是一款新型小分子Kv7.2/Kv7.3钾通道开放剂，主要开发适应症是癫痫和抑郁症。 Kv7.2/Kv7.3电压门控钾通道在大脑神经元轴突周围和轴突上的表达，是一个特别有吸引力的靶点。这些抑制性离子通道在靠近动作电位阈值的神经膜去极化对抗癫痫的过度兴奋起着制约作用，增强Kv7.2/Kv7.3通道开放的药物已被证明能减少癫痫发作。2011年，瑞替加滨被FDA批准为治疗癫痫的抗惊厥药物，但由于存在严重的皮肤及视网膜色素沉积等毒副作用，已经退市。与之相比，XEN1101有更高的体外和体内活性，瑞替加滨需要每天给药三次，而XEN1101每天给药一次，且没有色素沉积等问题。临床二期数据显示，XEN1101高剂量组癫痫发作频率相比基线降低52.8%，而安慰剂组只有18.2%。国内方面，上海药物所研发的派恩加滨同样瞄准这一靶点。而与瑞替加滨相比，派恩加滨的化学性质、活性、药代和安全性特征均显著优化，没有色素沉积风险。临床一期试验证明其具有良好的安全和代谢特性，目前出于二期阶段。再比如，Epidiolex是一种首创运用大麻成分的抗癫痫疗法，也是首个获批用于DS的药物，其主要成分大麻二酚（CBD）是一种多靶点分子，被证实具有明显抗癫痫活性。不过，CBD抗癫痫作用的分子机制仍不清楚，其可能的治疗靶点包括离子通道、转运体和跨膜信号蛋白，具体抗癫痫作用的机制仍有待研究。而最新研究显示，LPI-GPR55信号传导通路是CBD抗癫痫靶点的潜在调节因子，在联合用药方面，CBD也为对GABAAR调节剂（例如苯二氮卓类药物）无效的难治性癫痫患者提供了一种潜在的治疗选择。而在新机制研究方面，武田制药8.65亿美元收购而来的胆固醇24羟化酶（CH24H）抑制剂soticlestat，属于一个全新的抗癫痫作用机制，是通过抑制CH24H活性，减少胆固醇转化为24S-羟基胆固醇，从而降低谷氨酸能通路的兴奋性，减少癫痫发作。积极的二期试验结果为DS和LGS患者提供了新的药物选择的可能性，尤其是那些对现有药物不敏感的患者。然而，三期试验双双折戟。总体来看，目前在研治疗方法主要针对遗传学、离子通道和其他神经递质，以及其他潜在性FIC干预措施，比如干细胞、肠道微生物组、AAV9基因疗法等在进行早期研究，也为患者带来了更多新希望。从趋势来看，癫痫新疗法的研究不再局限于发作的控制，而是包括从发病机制的根源上改变癫痫发作的治疗及预后情况。总结需要承认的是，尽管新的突破每天都有可能发生，但这尚无法彻底改变CNS疾病新药研发的困境。就在上半年，一些药企在研癫痫新药遭遇失败。4月份，Addex宣布ADX71149在治疗对左乙拉西坦或布瓦西坦反应不佳的局灶性癫痫发作的2期研究失败；6月份，Marinus公司口服抗癫痫药物Ztalmy的静脉制剂ganaxolone治疗难治性癫痫持续状态开展的试验失败；武田的soticlestat，在治疗LGS及DS这两种难治性癫痫综合征的三期试验均未达主要终点；对此，武田表示，在16周的治疗中，治疗应答率、护理人员和临床医生对病情改善的总体印象以及癫痫发作强度和持续时间尺度都发生了显著变化。总体数据呈积极趋势，希望与监管机构商讨下一步行动。在号称“研发黑洞”的CNS领域，也的确需要武田这种屡败屡战的精神。期待新的革命性突破，早日到来。

并购临床2期

2024-11-01

·BioPharmaDive

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug

Today, a brief rundown of news from Regeneron Pharmaceuticals and Madrigal Pharmaceuticals, as well as updates from UCB, AbbVie and PTC Therapeutics that you may have missed.Shares of Regeneron Pharmaceuticals fell nearly 10% amid growing uncertainty about the future sales of its flagship Eylea franchise. Regeneron has been looking to a new high-dose version of Eylea to ward off competition from Roches Vabysmo and emerging biosimilar threats. But at $392 million, third-quarter sales missed consensus estimates and fell below the trajectory of Vabysmos matched-quarter revenues, reflecting slower-than-expected adoption, wrote Leerink Partners analyst David Risinger. Still, data readouts expected in the months ahead on drugs for blood clots, lung cancer and obesity could help refocus [the] story, wrote RBC Capital Markets Brian Abrahams in a separate note. Ben FidlerUCB said Thursday there were bright spots in a failed study testing the companys experimental drug for Alzheimers disease. The drug, called bepranemab, binds to a specific region on tau, a protein with well-established ties to Alzhiemers. While the mid-stage trial missed its main goal, UCB said key secondary objectives indicated its drug can slow cognitive decline and the accumulation of tau better than a placebo. After-the-fact analyses also found certain participants who received a high dose of bepranemab experienced 29% slower disease progression. Chief Scientific Officer Alistair Henry said the company is deeply encouraged by the results. Jacob BellSales of Rezdiffra, Madrigal Pharmaceuticals recently approved drug for metabolic dysfunction-associated steatohepatitis, or MASH, widely beat Wall Street expectations during the third quarter. Earnings reported by Madrigal Thursday show Rezdiffra sales totaled $62 million, well above the consensus forecast of around $36 million. Madrigal said that, as of Sept. 30, insurance policies were in place for more than 80% of people covered by private payers in the U.S. Shares in Madrigal, which had already impressed in August with its fast launch, climbed by nearly 40% through Friday morning. Ned PagliaruloAbbvie will work with biotech startup EvolveImmune Therapeutics to develop multispecific antibody drugs for cancer, the companies said Thursday. The deal hands Abbvie an option to license T cell engagers EvolveImmune designs with certain tweaks to boost their potency. AbbVie is paying the startup $65 million in cash and an equity investment to start the deal, and could add another $1.4 billion in future option fees and milestones. Ben FidlerOne other biopharmaceutical company bid to acquire Longboard Pharmaceuticals, but withdrew its offer of $60 per share before Lundbeck secured an acquisition agreement at the same price on Oct. 14. Longboard also contacted three other pharmas, but none expressed interest in discussing a buyout. The background of the $2.6 billion deal, disclosed via a securities filing Wednesday, also shows that Lundbeck upped its offer five times, from an initial proposal of $29 per share. Ned PagliaruloThe Food and Drug Administration will again evaluate whether to approve PTC Therapeutics Translarna for Duchenne muscular dystrophy, the company announced Wednesday. The agency previously rejected PTCs drug, which has long been available in Europe but may soon be withdrawn there due to questions about its effectiveness. The latest U.S. review is the result of PTCs resubmission and, as a result of the company originally filing its application over the FDAs protest, wont be reviewed on typical agency timelines. PTC believes the totality of evidence, including data from a patient registry, proves Translarnas benefits. But, Leerink Partners analyst Joseph Schwartz wrote, we're not getting our hopes up given the FDA's historically overwhelmingly negative view of the drug. Ben Fidler '

上市批准并购

2024-10-24

·PRNewswire

Jade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million

Mr. Frohlich, formerly Chief Operating Officer of Chinook Therapeutics, brings 20+ years of leadership experience; Dr. Kocinsky offers deep expertise in developing therapies for autoimmune and kidney diseases Board of Directors, comprised of industry veterans in science, business, and strategy, will support the company's growth Expanded financing to accelerate clinical development of Jade's novel therapies targeting autoimmune diseases with significant unmet need VANCOUVER, BC and SAN FRANCISCO, Oct. 24, 2024 /PRNewswire/ -- Jade Biosciences, Inc. ("Jade"), a biotechnology company dedicated to developing best-in-class therapies for patients living with autoimmune diseases, today announced the appointment of Tom Frohlich as Chief Executive Officer (CEO) and Hetal Kocinsky, M.D., as Chief Medical Officer (CMO). The company also introduced its newly formed Board of Directors, marking a significant step in the company's growth trajectory. Jade has extended its financing, bringing the total raised to $95 million. The financing round adds Frazier Life Sciences and Versant Ventures to an investor syndicate that includes Fairmount, Venrock Healthcare Capital Partners, Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP. Strategic Appointments to Lead Jade's Next Growth Phase Tom Frohlich, Chief Executive Officer Mr. Frohlich, a biotech and pharma industry veteran, brings over 20 years of experience in company building, business strategy, and product development. Before joining Jade, he co-founded and served as Chief Operating Officer (COO) of Chinook Therapeutics, where he guided the company's growth through to its $3.2 billion acquisition by Novartis in 2023. He also held leadership roles at Arbutus Biopharma, Johnson & Johnson, and Merck, managing key areas such as commercial strategy and business development. "I am honored to join Jade Biosciences and lead this talented team through such an exciting time," said Frohlich. "With a strong balance sheet, world-class investors, and an experienced leadership team, we are well-positioned to advance therapies that will transform patient care in autoimmune diseases." Hetal Kocinsky, M.D., Chief Medical Officer Dr. Kocinsky brings deep expertise in drug development, having led clinical programs from early-stage research to regulatory approvals across multiple therapeutic areas. Most recently, she served as Vice President of Translational Medicine at Chinook and held leadership roles at Apellis and Achillion Pharmaceuticals. A board-certified pediatric nephrologist, she also spent time as an Assistant Professor at the Yale School of Medicine. "I look forward to working alongside the team at Jade in our quest to deliver breakthrough therapies to patients in need," said Dr. Kocinsky. "With my background in translational medicine and experience navigating complex clinical landscapes, I look forward to accelerating solutions that can redefine care for patients with autoimmune diseases." New Board of Directors Brings Industry Expertise and Strategic Insight Jade's newly formed Board of Directors is led by Board Chairman Eric Dobmeier, former President and CEO of Chinook Therapeutics, and brings together industry leaders with expertise across science, business operations, and corporate strategy. The board includes: Chris Cain, Ph.D. – Director of Research, Fairmount Funds Management LLC Eric Dobmeier – Board Chairman, Venture Partner, Samsara BioCapital Tom Frohlich – CEO, Jade Biosciences Tomas Kiselak – Managing Member, Fairmount Funds Management LLC Lawrence Klein, Ph.D. – CEO of Oruka Therapeutics Erin Lavelle – Former COO and CFO at Profound Bio, Eliem Therapeutics; additional leadership roles at Alder BioPharmaceuticals and Amgen About Jade Biosciences Jade Biosciences is developing transformative therapies with the goal of redefining the standard of care for autoimmune diseases. The company launched in July 2024 and has raised $95 million from a strong slate of investors: Fairmount, Venrock Healthcare Capital Partners, Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, Braidwell LP, Frazier Life Sciences, and Versant Ventures. Jade's portfolio was engineered by Paragon Therapeutics. For more information, visit JadeBiosciences.com and follow us on LinkedIn. Media Contact [email protected] SOURCE Jade Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更并购IPO

100 项与 H. Lundbeck A/S 相关的药物交易

登录后查看更多信息

100 项与 H. Lundbeck A/S 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月25日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

氢溴酸伏硫西汀 ( 5-HT1A receptor x 5-HT1B receptor x 5-HT1D receptor x 5-HT3 receptor x 5-HT7 receptor x SERT )	重度抑郁症更多	批准上市
盐酸美金刚 ( NMDA receptor )	阿尔茨海默症更多	批准上市
草酸艾司西酞普兰 ( 5-HT receptor x SERT )	社交恐怖症更多	批准上市
舍吲哚 ( 5-HT2A receptor x ADRA1 x D2 receptor )	精神分裂症更多	批准上市
盐酸纳美芬 ( Opioid receptors x κ opioid receptor x μ opioid receptor )	酗酒更多	批准上市